What is our Investment Case?

In becoming the trusted global leader in access to medicines, the Group has consistently delivered healthy financial performances and returns. Below are the reasons to invest in Clinigen.

Unique combination of businesses

By utilising Clinigen's balanced portfolio, across the services and products businesses, we offer access to medicines at the key stages of the pharmaceutical product lifecycle.

Operations: 3
Commercial Medicines: 46%
Unlicensed Medicines: 44%
CTS: 10%
Global Capability

We have built a global supply chain and distribution network, organically, through acquisitions and partnerships, providing local market knowledge supported by global expertise.

Locations: 13
Countries supplied: 108
Experienced Management Team

We have an experienced and diverse Group and regional management, with a track record of delivering strong growth every year since inception.

Market-leading Positions

We are the market-leader in CTS and Unlicensed Medicines

#1

Unparalleled Knowledge and Expertise

We are experts in the supply and distribution of unlicensed medicines.

Significant Long-Term Growth Potential

The business can grow both through organic growth, with an increasing exposure to emerging pharmaceutical growth markets and through acquisition.

Highly Cash Generative

We generate strong cash returns which are underpinned by strong credit control and working capital management.

Cash generated from operations:

£64.1m

Trusted Ethical Supplier

We have deep well-established relationships with pharmaceutical companies
and pharmacists.

Relationships with big pharma:
31 of top 50 pharma companies

Customer base:
> 10,000 healthcare professionals (‘HCPs’)